Tags : cemiplimab

Regeneron Collaborates with BioNTech to Advance the Combination of FixVac

Shots: The two companies collaborated to jointly conduct P-II study combining BNT111 FixVac and Libtayo in patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV cutaneous melanoma with the expected initiation of the study in Q4’20 The companies will equally share the development costs for the clinical trial and will contribute their products for the trial. […]Read More

Sanofi and Regeneron Report Results of Libtayo (cemiplimab) in a

Shots: Shots: The ongoing P-II study involves assessing Libtayo (300mg, IV, q3w) for up to 93 wks. or until disease progression, unacceptable toxicity, withdrawal of consent or confirmed complete response in 132 patients with advanced BCC who were intolerant to prior HHI therapy The P-II study results: ORR (29% in patients with LA disease) with […]Read More

Regeneron and Sanofi’s Libtayo (cemiplimab) Receives European Commission’s Approval for

Shots: The conditional marketing authorization is based on the results from P-II EMPOWER-CSCC-1 (Study 1540) and supported by two advanced CSCC expansion cohorts from P-I study evaluating a Libtayo in patients with advanced CSCC The conditional approval is to meet unmet needs in advance CSCC, and the companies will generate additional data supporting the benefit-risk […]Read More